Projects

Clinical trials and research projects on DAO Deficiency:

2018-2019

Effect to Gastrointestinal Barrier Function During Laparoscopic Gastrectomy With Deep vs Moderate Neuromuscular Blockade.

Link to the Clinical Trial page in NIH ClinicalTrials.gov

Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborator: Wu Jieping Medical Foundation
Information provided by (Responsible Party): The First Affiliated Hospital with Nanjing Medical University

Brief Summary:

On the basis of moderate pneumoperitoneum pressure(10 mmHg), this study evaluates the effect of different level of neuromuscular blockade to gastrointestinal barrier function during laparoscopic gastrectomy. 60 patients are randomized to 2 arms ,The patients in deep NMB（PTC=1-2）will receive high dose rocuronium ;While the patients in moderate NMB（TOF=1-2）will receive moderate dose rocuronium.

Detailed Description:

Different level of neuromuscular blockade can affect the demand of pneumoperitoneum pressure,while high level of pneumoperitoneum pressure may cause some damage to gastrointestinal barrier which is important to the recovery of the patient. In this study,we will evaluate the effect of different level of neuromuscular blockade to the barrier by DAO and D-lactic in plasma, the microstructural changes of intestinal tract will be observed under scanning electron microscope and the recovery of intestinal function will be recorded.

Study design:

Study Type:	Interventional (Clinical Trial)
Estimated Enrollment:	60 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Effect to Gastrointestinal Barrier Function During Laparoscopic Gastrectomy With Deep vs Moderate Neuromuscular Blockade.
Estimated Study Start Date:	January 1, 2019
Estimated Primary Completion Date:	December 31, 2019
Estimated Study Completion Date:	December 31, 2019

2017-2019

DIAMINE-OXIDASE (DAO) TREATMENT ON PATIENTS WITH NON-ALLERGIC RHINITIS: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL TO ENSURE SAFETY AND EFFICACY.

1.Mayo¹, GN. Esquía¹, MJ. Rial²

¹Otorhinolaryngology Department.

²Allergology Department.

Complexo Hospitalario Universitario A Coruña (CHUAC).

Project co-sponsored by DR Healthcare

2016-2019

OBTAINING PROBIOTIC MICROORGANISMS WITH ENDOGENOUS DAO ACTIVITY.

M.Carmen Vidal Carou, Mariluz latorre, Teresa Veciana, Oriol Comas.

Universidad de Barcelona

Project co-sponsored by DR Healthcare, included in the Ris3Cat Food Community (Ris3Cat is an organization of the Catalan Government designed to promote R&D projects)

Project co-funded by the European Union through the European Regional Development Fund